Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy

Drug and Alcohol Dependence

Volumn 134, Issue 1, 2014, Pages 414-417

  Jones, Hendrée E ^a,b   Dengler, Erin ^c   Garrison, Anna ^d   O'Grady, Kevin E ^e   Seashore, Carl ^a   Horton, Evette ^a   Andringa, Kim ^a   Jansson, Lauren M ^b   Thorp, John ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON AND LEE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

Buprenorphine; Neonatal abstinence syndrome; Neonate; Opioid use disorder; Pregnancy

Indexed keywords

BUPRENORPHINE; MORPHINE; OPIATE AGONIST; PLACEBO;

APGAR SCORE; ARTICLE; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; DELIVERY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HUMAN; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN CARE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PARALLEL DESIGN; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; WITHDRAWAL SYNDROME;

BUPRENORPHINE; NEONATAL ABSTINENCE SYNDROME; NEONATE; OPIOID USE DISORDER; PREGNANCY;

BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84890239286     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.11.006     Document Type: Article

References (14)

1. Bakstad B., Sarfi M., Welle-Strand G.K., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur. Addict. Res. 2009, 15:128-134.
2. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006, 101:275-281.
3. Hytinantti T., Kahila H., Renlund M., Jarvenpaa A.L., Halmesmaki E., Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr. 2008, 97:1040-1044.
4. Jones H.E., Johnson R.E., Jasinski D.R., O'Grady K.E., Chisholm C.A., Choo R.E., Crocetti M., Dudas R., Harrow C., Huestis M.A., Jansson L.M., Lantz M., Lester B.M., Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005, 79:1-10.
5. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., O'Grady K.E., Selby P., Martin P.R., Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:2320-2331.
6. Jones H.E., Fischer G., Heil S.H., Kaltenbach K., Martin P.R., Coyle M.G., Selby P., Stine S.M., O'Grady K.E., Arria A.M. Maternal Opioid Treatment: Human Experimental Research (MOTHER): approach, issues, and lessons learned. Addiction 2012, 107(Suppl. 1):28-35.
7. Jones H.E., Heil S.H., Baewert A., Arria A.M., Kaltenbach K., Martin P.R., Coyle M.G., Selby P., Stine S.M., Fischer G. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012, 107(Suppl. 1):5-27.
8. Jones H.E., Jansson L.M., O'Grady K.E., Kaltenbach K. The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicol. Teratol. 2013, 39:110-115.
9. Kacinko S.L., Jones H.E., Johnson R.E., Choo R.E., Huestis M.A. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin. Pharmacol. Ther. 2008, 84:604-612.
10. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006, 82:250-257.
11. Metz V., Jagsch R., Ebner N., Wurzl J., Pribasnig A., Aschauer C., Fischer G. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum. Psychopharmacol. 2011, 26:412-421.
12. O'Connor A., Alto W., Musgrave K., Gibbons D., Llanto L., Holden S., Karnes J. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes. J. Am. Board Fam. Med. 2011, 24:194-201.
13. O'Grady K.E., Jones H.E., Jansson L.M., Kaltenbach K. Response to Wouldes and Woodward: maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol. Teratol. 2013, 39:116-118.
14. Patrick S.W., Schumacher R.E., Benneyworth B.D., Krans E.E., McAllister J.M., Davis M.M. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. J. Am. Med. Assoc. 2012, 307:1934-1940.